Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Heparinization in Cerebral Angiography (SELECT)
NCT06365398Phase 4Completed
- Sponsor
- Xuanwu Hospital
- Start
- Jan 2018
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of heparin in cerebrovascular disease (3 arms), sponsored by Xuanwu Hospital. Primary endpoint: postoperative cerebral infarction. Started Jan 2018; status: completed.
02
Drugs
heparin
03
Conditions
cerebrovascular disease
Beyond the preview
Go deeper on NCT06365398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365398.